Considerations for prophylactic use of antiarrhythmic drugs in acute myocardial infarction.
D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D001285:Atropine / Q000627:therapeutic use; D001949:Bretylium Compounds / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000503:physiopathology; D006329:Heart Conduction System / Q000503:physiopathology; D006333:Heart Failure / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008012:Lidocaine / Q000008:administration & dosage / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D010672:Phenytoin; D001285:Atropine; D008012:Lidocaine; D011802:Quinidine; D011342:Procainamide